Zepbound

CVS will restore Zepbound coverage on October 1 and add Eli Lilly's newly approved Foundayo obesity pill to drug plans starting June 1. This expanded coverage could significantly increase market access for weight management medications.

Eli Lilly raised its full-year sales outlook by $2 billion driven by skyrocketing sales of diabetes/weight-loss drugs Zepbound and Mounjaro. This massive revenue increase demonstrates the commercial success of GLP-1 medications, positioning Lilly to capture significant market share in the growing obesity treatment sector.